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ABSTRACT
This study was designed to develop and validate a UPLC-MS/MS method for quantification of neratinib in human plasmsa.
Neratinib is an irreversible tyrosine kinase inhibitor against the pan-ErbB (ErbB-1, -2, -4) receptor. UPLC-MS/MS is an excellent
analytical methodology for rapid biomedical analysis, decreasing the time for analysis and maintaining good efficiency.
Crizotinib was used as internal standard (IS). Samples where extracted by plasma protein precipitation (PPT) procedure with
acetonitrile and methanol and analysis was performed on a C18 Acquity UPLC BEH
TM column. The ion transitions where recorded
in positive ion multiple reaction monitoring mode m/z 557.51® 112.17 for neratinib and m/z 450.0 ® 260.0 for IS. The mobile phase
used was methanol:water: formic acid (70:30:0.1 %, v/v/v) with a flow rate of 0.3 mL min–1. The linearity of the assay was found to
be 4–500 ng mL–1 for neratinib in human plasma with lower limit of quatification of 4 ng mL–1. The intra- and inter-assay precision
relative standard deviations did not exceed 10.99 and mean extraction recovery was found to be 69.12 ± 3.58.
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1. Introduction
In controlling critical cellular activities such as the cell migration,
cell cycle, cell survival and metabolism, cell differentiation and
proliferation, the receptor tyrosine kinase plays a very impor-
tant role.1 In various cancers hyperactivation of epidermal
growth factor receptor (EGFR) family of receptor tyrosine kinases
was observed and elevated levels of ErbB-2 and poor prognosis
in (approximately) 30 % cases of breast cancer is correlated with
over-expression.2–4 Monotherapy with transtuzumab4,5 which is
the standard treatment for ErbB-2-positive breast cancer pro-
vides only 15 % response rates, where as a combination of
transtuzumab with paclitaxel or chemotherapy increases the
success rate to 41 % and 50 %, respectively.5–6 The most common
problem with transtuzumab is the development of resistance.7
Neratinib (NTB) is a low molecular weight, potent, irreversible
inhibitor of EGFR, HER2 and HER4 tyrosine kinase activity2,8–10
and has exhibited promising preclinical activity alone or in with
combination pactitaxel or transtuzumab against HER2-over-
expressing cell lines.8,11–13 NTB is currently undergoing several
phase three clinical trials.14,15
In HER2-positive breast cancer patients with innate and ac-
quired trastuzumab resistance NTB was found to be an effective
anti-HER2 therapy alternative which counteracted the resistance.
Trastuzumab in comination with neratinib exhibit a synergistic
effect on each other compared to the use of either of the two
drugs alone.16
After a single oral dose of 120–800 mg of NTB in healthy sub-
jects in a fasting state the peak plasma NTB concentration (tmax)
was found to be 4–7 h, with a half-life of approximately 9–17 h.17
Literature review revealed a single publication regarding the
determination of NTB in human plasma samples using high
performance liquid chromatography mass spectrometry/mass
spectrometry (HPLC-MS/MS) methods.18 In this report, conven-
tional column (Genesis C18 column (50 × 2.1 mm, 4 µm particle
size) was used, whereas in our study (C18 Acquity UPLC BEH™
column 2.1 × 50 mm 1.7 µm particle size) was used along with an
UPLC-MS/MS system, which resulted in very low flow rate and
faster analysis without affecting the sensitivity of the method.
Since, the pharmacokinetic studies necessitates a drug assay that
is simple, selective, economical, requires small sample volume,
and has rapid turnaround time, the present paper bears improve-
ment over the reported methods.19
UPLC is a new category of separation science which builds
upon well-established principles of liquid chromatography, The
column used has sub-2 µm porous particles and can operate at
high mobile phase linear velocities thus producing significant
reduction in time for separation and consumption of solvents.
Application of the UPLC system results in a three-fold decrease
in analysis time to conventional high-performance liquid chro-
matography using 3 µm particle size columns and a nine times
decrease in time compared to 5 µm particle size columns.20–25
Acquity UPLC columns contain hybrid X-Terra sorbent, which
utilizes a bridged ethyl siloxane/silica hybrid (BEH) structure,
ensures column stability under high pressure and a wide
pH range (1–12).25
In all the documented references, no validated UPLC-MS/MS
method has been reported for the determination of NTB using in
human plasma. Therefore, in this study, a validated UPLC-MS/MS
method was developed and validated for analysis of NTB
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in human plasma. The proposed method is simple, cost-effective
and rapid for the quantification of NTB in human plasma.
2. Experimental
2.1. Materials and Methods
NTB was obtained from Weihua Pharma Co., Limited,
Zhejiang, China. Crizotinib was purchased from Tocris Bioscience
(Shanghai, China). Methanol and acetonitrile (HPLC-grade),
and ammonium acetate were procured from Winlab Laboratory
(London, UK), and formic acid was procured from BDH Labora-
tory(Poole Dorset, UK). Other chemicals used in the study were
of analytical grade. Human plasma was obtained from normal
healthy volunteers at King Khalid University Hospital (Riyadh,
Saudi Arabia), and ethical approval was obtained from the insti-
tutional review board of the King Khalid University Hospital
(approval no. 14/3087/IRB). The samples were kept frozen at
–80 °C until analysis. Milli Q advantage (0.22 µm, Millipore,
Moscheim Cedex, France) water was used to prepare the aqueous
solutions.
2.2. Chromatography and Tandem Mass Spectrometry
Systems
The chromatopraphy was performed using an Acquity UPLC
system (Waters Corp., Milford, MA, USA) equipped with a
temperature-controlled sample and column compartments and
coupled to Acquity triple quadrupole (TQD) tandem mass spec-
trometer (Waters Corp., Milford, MA, USA). Chromatographic
separations were executed on a 2.1 × 50 mm C18 column packed
with 1.7 µm particles (ACQUITY UPLC BEH Waters) capable of
bearing pressure of 15 000 psi. Mobile phase was methanol:
water:formic acid in the ratio (70:30:0.1 %, v/v/v) with a flow rate
of 0.3 mL min–1.
Detection of NTB and the IS was carried out by multiple reaction
monitoring (MRM) using mass-to-charge (m/z) transitions of
557.29 ® 112.17 for NTB (Fig. 1), and 450.0 ® 260.0 for crizotinib
(IS), with a dwell time of 0.0146 seconds. The capillary voltage for
the ESI source, the cone voltages and collision energy for NTB
and IS were optimized. The UPLC-MS/MS system was controlled
by Mass Lynx software (SCN 805; Version 4.1, from Waters USA).
2.3. Quality Control Samples and Calibration Standards
Standard stock solutions of 1 mg mL–1 were prepared in methanol
for both NTB and crizotinib. The stock solution of NTB was
serially diluted to prepare working standards in the required
concentration range with methanol. The calibration standards
for NTB were prepared by spiking plasma with working
standard solutions to yield calibration range from 4 to 500
ng mL–1 (4, 8, 16, 32, 64, 128, 256, and 500). The quality control
(QC) sample solutions for NTB were separately prepared in
methanol similarly as calibration standards at four different
levels: 4 ng mL–1 lower limit of quantitation (LLOQ), 12 ng mL–1
low quality control (LQC) (LQC, within three times of the
LLOQ), 200 ng mL–1 middle quality control (MQC) and 400 ng
mL–1 high quality control (HQC). working standard solution for
internal standard was prepared from crizotinib standard stock
solution (1 mg mL–1) in methanol to get 1 µg mL–1.
2.4. Sample Preparation
To 200 µL of plasma sample was added 10 µL (1 µg mL–1) of IS
with the exception of the blank sample where no IS was added.
These samples were vortexed for a period of 30 seconds after
which 200 µL of methanol were added and vortex mixed again
for another 30 seconds. After vortexing, a further 500 µL of
acetonitrile were added to the sample tube. The resulting
mixture was again vortexed for a period of 1.5 min and cold
centrifuged at 10000 rpm for 10 min. The supernatant fluid was
separated in a glass tube and evaporated to dryness using
TurboVap LV evaporator (Model: C103199, Biotage, USA) at
40 °C under a gentle nitrogen stream. The residue was reconsti-
tuted with 200 µL of mobile phase and transferred to UPLC vials.
5 µL sample volumes were subjected for the analysis by
UPLC-MS/MS in MS/MS mode.
2.5. Validation of the Bioanalytical Method
The method was validated as per US-FDA and EMEA guide-
lines in human plasma.26,27 To evaluate linearity, an eight-point
standard plasma calibration curve (4–500 ng mL–1) was prepared
and assayed in triplicate on three separate days. Peak area ratio
of the NTB to internal standard were used for the construction of
calibration curves. The curve fitting was achieved with 1/x2 as
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Figure 1 The product ion spectra of neratinib.
the weighting factor using least-squares linear regression. Back
calculations from these curves were used to determine NTB con-
centrations in the calibration standard solutions and to deter-
mine the concentrations of the analyte. To determine the accu-
racy and precision of the method QC samples at four different
concentration levels 4 ng mL–1 lower limit of quantitation
(LLOQ), 12 ng mL–1 low quality control (LQC), 200 ng mL–1 mid-
dle quality control (MQC) and 400 ng mL–1 high quality control
(HQC) were used. On three different days (n =6) the QC con-
centration level were quantified with seperate calibration
curves. The accuracy and the precision for each QC level was
evaluated by calculating the recovery percent and relative stan-
dard deviation (RSD) of the measured concentrations, respec-
tively. The accuracy was within ±15 % and the precision, (intra-
and inter-day) was required to be less than 15 %. Extraction
recovery for NTB in spiked plasma samples (n = 6) was estimated
by comparing peak area of neratinib in different QC concentra-
tions (LQC, MQC and HQC) to extracted drug-free plasma peak
area spiked with the same amount of NTB preceding chromato-
graphic analysis. Extraction recovery for IS (n = 6) was deter-
mined in a similar way as for the QC samples. The matrix effect
can cause either ion suppression or ion enhancement.28 For NTB
the effect was evaluated by comparing the peak areas for
extracted drug free plasma QC samples (LQC, MQC and HQC)
to the peak area of neat solvent spiked with similar concentra-
tion. The bench top stability of the NTB was studied in plasma at
room temperature for 6 h. QC samples were kept in an
autosampler for 48 h (8 °C) to determine the stability of the
compound during analysis. The stability over three freeze-thaw
cycles was evaluated for the QC samples stored at –80 °C for
plasma. Determination of long-term stability was carried out by
storing test samples at around –80 °C for 60 days. Stock solution
stability for NTB in methanol was determined at 25 °C for 24 h
and also in refrigerated condition (4–8 °C) for 30 days prior to
chromatographic analysis. Dilution integrity was carried out
for NTB to evaluate effect of dilution on concentration above
ULOQ as some samples may need dilution during real time
samples analysis.
3. Results and Discussion
3.1. Chromatographic Conditions Optimization
100 ng mL–1 of NTB and the IS were used for the tuning of the
mass spectrometer in positive ionization mode with ESI as the
ionization source. The MS parameters were optimized for
quantification of NTB and IS and these parametes comprised
the ESI source temperature, capillary, collision energy and cone
voltage, flow rate of cone gas, desolvation temperature and gas.
The most important parameters amongst them were collision
energy and cone voltage. Cone voltage (2–100) V and collision
energies (2–80) eV ramp were used to determine the optimum
cone voltage and collision energy and were found out to be 46 V
and 30 eV, respectively for m/z 557.51 ® 112.17 transition. The op-
timum cone voltage and collision energy using ramp for the IS,
450.0 ® 260.0 transition were found out to be of 48 V and 28 eV,
respectively.
3.2. Optimization of Sample Processing
Sample preparation was performed using the protein precipi-
tation technique (PPT)28. PPT can be helpful in producing clean
samples as these are a requisite in order to avoid endogenous
substances from interfereing with the analysis and functioning
of LC and MS/MS systems. Clean samples are also important for
minimizing ion suppression and matrix effects.
3.3. Selectivity
For assessing the selectivity of the method, chromatograms of
blank plasma were compared with the corresponding spiked
LLOQ samples. Blank human plasma samples (six different
batches) were analyzed to establish the peaks which may be due
to the likely biological plasma constituents. For determination
of NTB and IS in plasma the method was found to be selective.
As is evident from Fig. 2A and Fig. 2B, blank plasma did not show
any interference at the analyte and IS retention time. LLOQ and
LQC chromatograms are represented in Fig. 2C and Fig. 2D, and
Fig. 2E and Fig. 2F represent HQC and IS chromatograms.
3.4. Linearity and Sensitivity
Calibration curves for NTB in human plasma were generated
using area ratio of (NTB/IS) as a function of NTB concentration.
Determination coefficients (r2) during the course of validation
was found to be greater than 0.996. Linearity of the method was
found to be 4–500 ng mL–1. LLOQ of 4 ng mL–1 of NTB in plasma
was adequate for investigation of its pharmacokinetic behav-
iour.
3.5. Accuracy and Precision
The inter- and intra-day accuracy and precision values for
QC samples are presented in Table 1. The intra- and inter- day
(% CV) values for plasma were 4.29–10.99 % and 2.71–7.39 %,
respectively, and these values are within the range of tolerable
limits26,27 for precision and accuracy.
3.6. Recovery
The extraction recoveries for NTB at the LQC, MQC and HQC
are presented in Table 2. The extraction recovery for NTB
(mean ± S.D.) was 69.12 ± 3.58 % and for the IS (crizotinib) the
mean recovery at the concentration tested was 85.19 ± 9.64 %.
Although, this extraction recovery was relatively low, the sensi-
tivity of PPT with methanol and acetonitrile as sample
pre-treatment was adequate, since the desired LLOQ for all
RESEARCH ARTICLE T.A. Wani, S. Zargar and A. Ahmad, 95
S. Afr. J. Chem., 2015, 68, 93–98,
<http://journals.sabinet.co.za/sajchem/>.
Table 1 Intra- and inter-day precision and accuracy of NTB in human
plasma.
Spiked conc. Run Measured conc. Precision Accuracy
/ng mL–1 /ng mL–1 ± S.D. (RSD/%) (recovery/%)
Intraday variation (six replicate at each concentration)
4 1 4.31 ± 0.38 8.82 107.75
2 3.82 ± 0.42 10.99 95.50
3 4.39 ± 0.42 9.57 109.75
12 1 11.85 ± 1.16 9.79 98.75
2 12.51 ± 0.96 7.67 104.25
3 12.21 ± 1.03 8.44 101.75
200 1 188.25 ± 13.25 7.04 94.12
2 196.21 ± 11.12 5.67 98.10
3 212.39 ± 15.98 7.52 106.19
400 1 423.38 ± 18.15 4.29 105.84
2 403.85 ± 22.73 5.63 100.96
3 390.25 ± 19.86 5.09 97.56
Interday variation (18 replicates at each concentration)
4 4.17 ± 0.31 7.39 104.33
12 12.19 ± 0.33 2.71 101.58
200 198.95 ± 12.30 6.18 99.48
400 405.83 ± 16.65 4.10 101.46
analytes were achieved with a S/N >10. Moreover, the robust-
ness of this sample pre-treatment method was sufficient26 with
CV values <8.39 % over the entire concentration range. Protein
precipitation seemed to be a fast and simple one-step sample
pre-treatment procedure for the analysis of NTB in plasma.
3.7. Matrix Effect
Three different lots of plasma were evaluated at each QC level
(LQC,MQC and HQC) and per cent nominal concentrations
with RSD. were observed to be (91.11 ± 1.85 %, 83.26 ± 1.77 %,
and 85.64 ± 1.07 %, respectively). A similar analysis was performed
for the IS and the per cent nominal concentration with RSD. was
(93.27 ± 2.65 %). The results indicate that ion suppression or
enhancement from plasma matrix was consistent for this analyt-
ical method and would not interfere in the measurement of the
analytes.
3.8. Stability
NTB spiked plasma samples were quite stable at 25 °C for
a period of 6 h, in the autosampler at 8 °C for a period of 48 h,
during three freeze–thaw cycles and for 60 days at –80 °C. The
stock solution of NTB and IS were also stable for a period of
period of 30 days at (4–8 °C) (Table 3).
3.9. Dilution Integrity
As indicated in Table 3 the dilution integrity was maintained
after 2 and 4 times dilution and hence does not effect the analysis
of NTB in plasma.
4. Conclusion
A UPLC-MS/MS method for estimation of NTB in human
plasma was developed and validated. In all the documented
references, no method has been reported for the determination
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Figure 2 Retention time of analyte and IS in the blank plasma are shown in A and B respectively. C and D, represent chromatogram of LLOQ and
LQC, whereas representative chromatogram HQC and IS are shown in E and F, respectively.
Table 2 Recovery data of NTB (three QC samples) and crizotinib in
human plasma
Compound Spiked conc./ng mL–1 Recovery/% ± S.D.
NTB (analyte) 12 65.30 ± 8.39
200 69.65 ± 6.28
400 72.41 ± 6.19
Mean ± S.D. 69.12 ± 3.58
Crizotinib (IS) 50 85.19 ± 9.64
and validation of NTB using UPLC-MS/MS in human plasma.
The method was highly sensitive with high-throughput.
Samples were prepared by using simple PPT and each sample
had a run time of 2 min only. The developed method will be
useful for pharmacokinetic and toxicokinetic analysis of NTB
in humans.
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